Literature DB >> 28822782

Yellow fever vaccination: estimating coverage.

Annelies Wilder-Smith1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28822782     DOI： 10.1016/S1473-3099(17)30494-2

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  9 in total

Review 1.  Yellow Fever in Travelers.

Authors:  Annelies Wilder-Smith
Journal:  Curr Infect Dis Rep       Date:  2019-10-31       Impact factor: 3.725

2.  Differences between coverage of yellow fever vaccine and the first dose of measles-containing vaccine: A desk review of global data sources.

Authors:  Nedghie Adrien; Terri B Hyde; Marta Gacic-Dobo; Joachim Hombach; Akshaya Krishnaswamy; Philipp Lambach
Journal:  Vaccine       Date:  2019-06-29       Impact factor: 3.641

3.  Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study.

Authors:  Reinaldo de Menezes Martins; Maria de Lourdes S Maia; Sheila Maria Barbosa de Lima; Tatiana Guimarães de Noronha; Janaina Reis Xavier; Luiz Antonio Bastos Camacho; Elizabeth Maciel de Albuquerque; Roberto Henrique Guedes Farias; Thalita da Matta de Castro; Akira Homma
Journal:  Vaccine       Date:  2018-05-18       Impact factor: 3.641

4.  Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.

Authors:  Ismael Artur da Costa-Rocha; Ana Carolina Campi-Azevedo; Vanessa Peruhype-Magalhães; Jordana Grazziela Coelho-Dos-Reis; Jordana Rodrigues Barbosa Fradico; Thalles Souza-Lopes; Laise Rodrigues Reis; Larissa Chaves Freire; Christiane Costa-Pereira; Juliana Vaz de Melo Mambrini; Maria de Lourdes de Sousa Maia; Sheila Maria Barbosa de Lima; Tatiana Guimarães de Noronha; Janaina Reis Xavier; Luiz Antonio Bastos Camacho; Elizabeth Maciel de Albuquerque; Roberto Henrique Guedes Farias; Thalita da Matta de Castro; Akira Homma; Alessandro Pecego Martins Romano; Carla Magda Domingues; Reinaldo de Menezes Martins; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Front Immunol       Date:  2019-06-21       Impact factor: 7.561

5.  Integrated Early Warning Surveillance: Achilles' Heel of One Health?

Authors:  Laura Amato; Maria Grazia Dente; Paolo Calistri; Silvia Declich
Journal:  Microorganisms       Date:  2020-01-08

6.  The resurgence of yellow fever outbreaks in Nigeria: a 2-year review 2017-2019.

Authors:  Terna Nomhwange; Anne Eudes Jean Baptiste; Obi Ezebilo; Joseph Oteri; Lois Olajide; Kizito Emelife; Shehu Hassan; Erdoo R Nomhwange; Kennedy Adejoh; Faith Ireye; Eyo E Nora; Adamu Ningi; Blaise Bathondeli; Oyewale Tomori
Journal:  BMC Infect Dis       Date:  2021-10-11       Impact factor: 3.090

7.  A neutralizing-protective supersite of human monoclonal antibodies for yellow fever virus.

Authors:  Yan Li; Zhihai Chen; Lili Wu; Lianpan Dai; Jianxun Qi; Yan Chai; Shihua Li; Qihui Wang; Zhou Tong; Sufang Ma; Xiaomin Duan; Shuning Ren; Rui Song; Mifang Liang; Wenjun Liu; Jinghua Yan; George F Gao
Journal:  Innovation (Camb)       Date:  2022-09-15

8.  Limited evolution of the yellow fever virus 17d in a mouse infection model.

Authors:  Dieudonné Buh Kum; Niraj Mishra; Bram Vrancken; Hendrik Jan Thibaut; Annelies Wilder-Smith; Philippe Lemey; Johan Neyts; Kai Dallmeier
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

Review 9.  Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines.

Authors:  Gerardo Montalvo Zurbia-Flores; Christine S Rollier; Arturo Reyes-Sandoval
Journal:  Hum Vaccin Immunother       Date:  2021-05-11       Impact factor: 3.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.